Evaxion presents preclinical data on S. aureus vaccine candidate EVX-B1
Aug. 1, 2023
Evaxion Biotech A/S has presented promising results on EVX-B1, a vaccine against Staphylococcus aureus containing antigens identified using artificial intelligence. EVX-B1 induces strong immune responses, both cellular and humoral, that translate to a high level of protection in preclinical models for skin infection and sepsis.